Key features and details
- Rabbit polyclonal to Met (c-Met) (phospho Y1003)
- Suitable for: WB
- Reacts with: Mouse, Rat, Human
- Isotype: IgG
Product nameAnti-Met (c-Met) (phospho Y1003) antibody
See all Met (c-Met) primary antibodies
DescriptionRabbit polyclonal to Met (c-Met) (phospho Y1003)
Specificityab193270 detects endogenous level of Met (c-Met) only when phosphorylated at tyrosine 1003.
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide within Human Met (c-Met) (phospho Y1003) conjugated to Keyhole Limpet Haemocyanin (KLH). The exact sequence is proprietary. [Peptide sequence is around the phosphorylation site of tyrosine 1003 (V-D-Y(p)-R-A).]
Database link: P08581
- HepG2 cell extract
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 0.88% Sodium chloride, 50% Glycerol, 49% PBS
PBS is without Mg2+ and Ca2+.
Concentration information loading...
PurityImmunogen affinity purified
Purification notesab193270 was purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography using non-phosphopeptide.
Our Abpromise guarantee covers the use of ab193270 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500 - 1/1000. Predicted molecular weight: 155 kDa.|
FunctionReceptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity. Functions in cell proliferation, scattering, morphogenesis and survival.
Involvement in diseaseNote=Activation of MET after rearrangement with the TPR gene produces an oncogenic protein.
Note=Defects in MET may be associated with gastric cancer.
Defects in MET are a cause of hepatocellular carcinoma (HCC) [MIM:114550].
Defects in MET are a cause of renal cell carcinoma papillary (RCCP) [MIM:605074]. It is a subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into common renal cell carcinoma (clear cell, non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma.
Note=A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes.
Note=MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies.
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family.
Contains 3 IPT/TIG domains.
Contains 1 protein kinase domain.
Contains 1 Sema domain.
DomainThe kinase domain is involved in SPSB1 binding.
modificationsDephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365.
- Information by UniProt
- AUTS9 antibody
- c met antibody
- D249 antibody
ab193270 has been referenced in 2 publications.
- Mambetsariev I et al. Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology. J Clin Med 8:N/A (2019). PubMed: 31315252
- Hu H et al. Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. Cell 175:1665-1678.e18 (2018). PubMed: 30343896